The Technical Analyst
Codex DNA, Inc. [DNAY]
Exchange: NASDAQ Global Select Sector: Healthcare Industry: Medical - Devices
Codex DNA, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
8.33% $1.300
/ 4 jan 2023 @ 00:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 38.32 mill |
| EPS: | 0 |
| P/E: | 0 |
| Earnings Date: | N/A |
| SharesOutstanding: | 29.48 mill |
| Avg Daily Volume: | 0.0794 mill |
| RATING 2023-03-07 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Buy | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.170 - 1.430 ( +/- 10.00%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-08-31 | Kullback William J | Buy | 300 000 | Stock Option (right to buy) |
| 2023-08-28 | Kullback William J | Buy | 0 | |
| 2023-10-18 | Herrema Gregory J. | Buy | 229 787 | Stock Option (right to buy) |
| 2023-10-18 | Herrema Gregory J. | Buy | 153 191 | Common Stock |
| 2023-10-18 | Herrema Gregory J. | Buy | 0 |
| INSIDER POWER |
|---|
| 96.61 |
| Last 81 transactions |
| Buy: 30 855 803 | Sell: 22 356 163 |
Forecast:
01:40 - $1.182
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.300 (8.33% ) |
| Volume | 0.0199 mill |
| Avg. Vol. | 0.0794 mill |
| % of Avg. Vol | 25.12 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For DNAY
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
DNAY
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
Latest Press Releases
2022-11-02 16:19:00 - Press Release
Telesis Bio To Report Third Quarter 2022 Financial Results And Provide A Corporate Update On November 8
San diego, nov. 02, 2022 (globe newswire) -- telesis bio (nasdaq: dnay), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2022 financial results on tuesday, november 8, 2022, after the market closes. in conjunction with the release, management will host a conference call the same day at 1:30 p.m. pacific time / 4:30 p.m. eastern time to discuss the financial results and recent corporate highlights.
2022-08-02 16:05:00 - Press Release
Codex Dna To Report Second Quarter 2022 Financial Results On Tuesday, August 9, 2022
San diego, aug. 02, 2022 (globe newswire) -- codex dna, inc. (nasdaq: dnay), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its second quarter 2022 financial results on tuesday, august 9, 2022, after the market closes. in conjunction with the release, management will host a conference call on tuesday, august 9, 2022, at 1:30 p.m. pacific time / 4:30 p.m. eastern time to discuss the financial results and recent corporate highlights.
2022-06-02 08:03:00 - Press Release
Codex Dna To Present At The 2022 Jefferies Healthcare Conference
San diego, june 02, 2022 (globe newswire) -- codex dna, inc. (nasdaq: dnay), a pioneer in automated benchtop synthetic biology systems, today announced that todd r. nelson, phd, the company's chief executive officer, will present at the 2022 jefferies healthcare conference on friday, june 10th at 9:00 am eastern time / 6:00 am pacific time.
2022-05-03 08:03:00 - Press Release
Codex Dna To Report First Quarter 2022 Financial Results On Tuesday, May 10, 2022
San diego, may 03, 2022 (globe newswire) -- codex dna, inc. (nasdaq: dnay), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its first quarter 2022 financial results on tuesday, may 10, 2022, after the market closes. in conjunction with the release, management will host a conference call on tuesday, may 10, 2022, at 1:30 p.m. pacific time / 4:30 p.m. eastern time to discuss the financial results and recent corporate highlights.
2022-03-03 08:03:00 - Press Release
Codex Dna Announces Registration And Webcast Information For Upcoming R&d Webinar On March 29, 2022
San diego, march 03, 2022 (globe newswire) -- codex dna, inc. (nasdaq: dnay), a pioneer in automated benchtop synthetic biology systems, today announced details for its first investor r&d webinar. management will describe the future promise of the company's r&d pipeline, with a specific focus on its proprietary short oligo ligation assembly (sola) enzymatic dna synthesis technology.
Latest News
2022-11-12 20:53:40 - Seeking Alpha
Telesis Bio, Inc. (DNAY) Q3 2022 Earnings Call Transcript
Telesis Bio, Inc. (NASDAQ:DNAY ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Todd Nelson - CEO Brent Hunter - VP, Finance Conference Call Participants Brandon Couillard - Jefferies Operator Welcome to the Q3 2022 Telesis Bio Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
2022-11-08 21:04:09 - Zacks Investment Research
Codex DNA (DNAY) Reports Q3 Loss, Tops Revenue Estimates
Codex DNA (DNAY) delivered earnings and revenue surprises of 12.50% and 25.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-11-02 16:19:00 - GlobeNewsWire
Telesis Bio to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 8
SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2022 financial results on Tuesday, November 8, 2022, after the market closes. In conjunction with the release, management will host a conference call the same day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights.
2022-08-26 11:18:31 - Zacks Investment Research
Codex DNA (DNAY) Could Find Support Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Codex DNA (DNAY), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
2022-08-14 08:26:10 - Seeking Alpha
Codex DNA, Inc. (DNAY) CEO Todd Nelson on Q2 2022 Results - Earnings Call Transcript
Codex DNA, Inc. (NASDAQ:DNAY ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Todd Nelson - Chief Executive Officer Brent Hunter - VP of Finance Conference Call Participants Brandon Couillard - Jefferies Operator Good day, and thank you for standing by. Welcome to the Q2 2022 Codex DNA, Incorporated Earnings Conference Call.
2022-08-09 21:04:09 - Zacks Investment Research
Codex DNA (DNAY) Reports Q2 Loss, Tops Revenue Estimates
Codex DNA (DNAY) delivered earnings and revenue surprises of 1.96% and 22.94%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-08-02 16:05:00 - GlobeNewsWire
Codex DNA to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its second quarter 2022 financial results on Tuesday, August 9, 2022, after the market closes. In conjunction with the release, management will host a conference call on Tuesday, August 9, 2022, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights.
2022-06-02 08:03:00 - GlobeNewsWire
Codex DNA to Present at the 2022 Jefferies Healthcare Conference
SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that Todd R. Nelson, PhD, the company's chief executive officer, will present at the 2022 Jefferies Healthcare Conference on Friday, June 10th at 9:00 am Eastern time / 6:00 am Pacific Time.
2022-05-14 23:28:11 - Seeking Alpha
Codex DNA, Inc. (DNAY) CEO Todd Nelson on Q1 2022 Results - Earnings Call Transcript
Codex DNA, Inc. (NASDAQ:DNAY ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Richard Lepke - Director, Investor Relations Todd Nelson - Chief Executive Officer Jennifer McNealey - Chief Financial Officer Conference Call Participants Brandon Couillard - Jefferies Paul Knight - KeyBanc Steven Mah - Cowen Operator Good afternoon, ladies and gentlemen and welcome to the Quarter One 2022 Codex DNA Incorporated Earnings Conference Call. [Operator Instructions] I would now like to turn the conference over to your host, Richard Lepke, Director of Investor Relations.
2022-05-03 08:03:00 - GlobeNewsWire
Codex DNA to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022
SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its first quarter 2022 financial results on Tuesday, May 10, 2022, after the market closes. In conjunction with the release, management will host a conference call on Tuesday, May 10, 2022, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights.